Why carry out this study?

Dupilumab has been shown to be an effective treatment in large double-blind randomised placebo-controlled trials and smaller real-world studies.

This study presents a tertiary centre experience on dupilumab effectiveness, safety and tolerability in a cohort of 164 patients followed over 12–30 weeks.

This is the first real-world study to evaluate the laboratory safety of dupilumab.

What was learned from the study?

This study showed that dupilumab is an effective and safe treatment for patients with atopic dermatitis.

Clinical response continues to improve past 16 weeks.

No detected laboratory abnormalities secondary to dupilumab.